Rheumatoid arthritis vaccine therapies: Perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis

Kenneth S. Rosenthal, Katalin Mikecz, Harold L. Steiner, Tibor T. Glant, Alison Finnegan, Roy E. Carambula, Daniel H. Zimmerman

Research output: Contribution to journalReview article

Abstract

The current status of therapeutic vaccines for autoimmune diseases is reviewed with rheumatoid arthritis as the focus. Therapeutic vaccines for autoimmune diseases must regulate or subdue responses to common self-antigens. Ideally, such vaccine would initiate an antigen-specific modulation of the T-cell immune response that drives the inflammatory disease. Appropriate animal models and types of helper cells and signature cytokine responses that drive autoimmune disease are also discussed. Interpretation of these animal models must be done cautiously because the means of initiation, autoantigens, and even the signature cytokine and helper cell (Th1 or Th17) responses that are involved in the disease may differ significantly from those in humans. We describe ligand epitope antigen presentation system vaccine modulation of T-cell autoimmune responses as strategy for the design of therapeutic vaccines for rheumatoid arthritis, which may also be effective in other autoimmune conditions.

Original languageEnglish (US)
Pages (from-to)891-908
Number of pages18
JournalExpert Review of Vaccines
Volume14
Issue number6
DOIs
StatePublished - Jun 1 2015
Externally publishedYes

Fingerprint

Active Immunotherapy
Antigen Presentation
Epitopes
Rheumatoid Arthritis
Vaccines
Ligands
Autoimmune Diseases
Autoantigens
Helper-Inducer T-Lymphocytes
Animal Models
Cytokines
T-Lymphocytes
Therapeutics
Autoimmunity
Antigens

Keywords

  • arthritis-specific antigens
  • arthritogenic epitopes
  • autoimmune disease
  • bystander effect
  • epitope spreading
  • rheumatoid arthritis
  • signature cytokine
  • therapeutic vaccines

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

Rheumatoid arthritis vaccine therapies : Perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis. / Rosenthal, Kenneth S.; Mikecz, Katalin; Steiner, Harold L.; Glant, Tibor T.; Finnegan, Alison; Carambula, Roy E.; Zimmerman, Daniel H.

In: Expert Review of Vaccines, Vol. 14, No. 6, 01.06.2015, p. 891-908.

Research output: Contribution to journalReview article

Rosenthal, Kenneth S. ; Mikecz, Katalin ; Steiner, Harold L. ; Glant, Tibor T. ; Finnegan, Alison ; Carambula, Roy E. ; Zimmerman, Daniel H. / Rheumatoid arthritis vaccine therapies : Perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis. In: Expert Review of Vaccines. 2015 ; Vol. 14, No. 6. pp. 891-908.
@article{2585d13a50a0455494f7729de820c014,
title = "Rheumatoid arthritis vaccine therapies: Perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis",
abstract = "The current status of therapeutic vaccines for autoimmune diseases is reviewed with rheumatoid arthritis as the focus. Therapeutic vaccines for autoimmune diseases must regulate or subdue responses to common self-antigens. Ideally, such vaccine would initiate an antigen-specific modulation of the T-cell immune response that drives the inflammatory disease. Appropriate animal models and types of helper cells and signature cytokine responses that drive autoimmune disease are also discussed. Interpretation of these animal models must be done cautiously because the means of initiation, autoantigens, and even the signature cytokine and helper cell (Th1 or Th17) responses that are involved in the disease may differ significantly from those in humans. We describe ligand epitope antigen presentation system vaccine modulation of T-cell autoimmune responses as strategy for the design of therapeutic vaccines for rheumatoid arthritis, which may also be effective in other autoimmune conditions.",
keywords = "arthritis-specific antigens, arthritogenic epitopes, autoimmune disease, bystander effect, epitope spreading, rheumatoid arthritis, signature cytokine, therapeutic vaccines",
author = "Rosenthal, {Kenneth S.} and Katalin Mikecz and Steiner, {Harold L.} and Glant, {Tibor T.} and Alison Finnegan and Carambula, {Roy E.} and Zimmerman, {Daniel H.}",
year = "2015",
month = "6",
day = "1",
doi = "10.1586/14760584.2015.1026330",
language = "English (US)",
volume = "14",
pages = "891--908",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Rheumatoid arthritis vaccine therapies

T2 - Perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis

AU - Rosenthal, Kenneth S.

AU - Mikecz, Katalin

AU - Steiner, Harold L.

AU - Glant, Tibor T.

AU - Finnegan, Alison

AU - Carambula, Roy E.

AU - Zimmerman, Daniel H.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - The current status of therapeutic vaccines for autoimmune diseases is reviewed with rheumatoid arthritis as the focus. Therapeutic vaccines for autoimmune diseases must regulate or subdue responses to common self-antigens. Ideally, such vaccine would initiate an antigen-specific modulation of the T-cell immune response that drives the inflammatory disease. Appropriate animal models and types of helper cells and signature cytokine responses that drive autoimmune disease are also discussed. Interpretation of these animal models must be done cautiously because the means of initiation, autoantigens, and even the signature cytokine and helper cell (Th1 or Th17) responses that are involved in the disease may differ significantly from those in humans. We describe ligand epitope antigen presentation system vaccine modulation of T-cell autoimmune responses as strategy for the design of therapeutic vaccines for rheumatoid arthritis, which may also be effective in other autoimmune conditions.

AB - The current status of therapeutic vaccines for autoimmune diseases is reviewed with rheumatoid arthritis as the focus. Therapeutic vaccines for autoimmune diseases must regulate or subdue responses to common self-antigens. Ideally, such vaccine would initiate an antigen-specific modulation of the T-cell immune response that drives the inflammatory disease. Appropriate animal models and types of helper cells and signature cytokine responses that drive autoimmune disease are also discussed. Interpretation of these animal models must be done cautiously because the means of initiation, autoantigens, and even the signature cytokine and helper cell (Th1 or Th17) responses that are involved in the disease may differ significantly from those in humans. We describe ligand epitope antigen presentation system vaccine modulation of T-cell autoimmune responses as strategy for the design of therapeutic vaccines for rheumatoid arthritis, which may also be effective in other autoimmune conditions.

KW - arthritis-specific antigens

KW - arthritogenic epitopes

KW - autoimmune disease

KW - bystander effect

KW - epitope spreading

KW - rheumatoid arthritis

KW - signature cytokine

KW - therapeutic vaccines

UR - http://www.scopus.com/inward/record.url?scp=84929299047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929299047&partnerID=8YFLogxK

U2 - 10.1586/14760584.2015.1026330

DO - 10.1586/14760584.2015.1026330

M3 - Review article

C2 - 25787143

AN - SCOPUS:84929299047

VL - 14

SP - 891

EP - 908

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 6

ER -